Fidi Koppel

1.6k total citations
6 papers, 192 citations indexed

About

Fidi Koppel is a scholar working on Applied Microbiology and Biotechnology, Clinical Biochemistry and Pharmacology. According to data from OpenAlex, Fidi Koppel has authored 6 papers receiving a total of 192 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Applied Microbiology and Biotechnology, 3 papers in Clinical Biochemistry and 2 papers in Pharmacology. Recurrent topics in Fidi Koppel's work include Antibiotic Use and Resistance (4 papers), Bacterial Identification and Susceptibility Testing (3 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Fidi Koppel is often cited by papers focused on Antibiotic Use and Resistance (4 papers), Bacterial Identification and Susceptibility Testing (3 papers) and Antibiotics Pharmacokinetics and Efficacy (2 papers). Fidi Koppel collaborates with scholars based in Israel, Italy and Switzerland. Fidi Koppel's co-authors include Mical Paul, Oren Zusman, Sergey Altunin, Habip Gedık, Yael Dishon Benattar, ‪Adi Turjeman‬‏, Dafna Yahav, Leonard Leibovici, Erica Franceschini and Cristina Mussini and has published in prestigious journals such as Water Research, Journal of Antimicrobial Chemotherapy and BMJ Open.

In The Last Decade

Fidi Koppel

6 papers receiving 190 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fidi Koppel Israel	5	149	108	73	58	31	6	192
Yael Dishon Benattar Israel	2	158 1.1×	122 1.1×	71 1.0×	50 0.9×	17 0.5×	2	170
Sergey Altunin Israel	3	158 1.1×	122 1.1×	71 1.0×	50 0.9×	17 0.5×	3	178
Fabiano Ramos Brazil	4	211 1.4×	163 1.5×	114 1.6×	49 0.8×	23 0.7×	12	265
Lamprini Galani Greece	8	188 1.3×	151 1.4×	85 1.2×	63 1.1×	22 0.7×	9	246
Drew Lewis United States	5	151 1.0×	106 1.0×	145 2.0×	73 1.3×	24 0.8×	10	276
Christopher Blunden United States	5	172 1.2×	74 0.7×	64 0.9×	93 1.6×	60 1.9×	7	240
Carlos Bergallo Argentina	3	98 0.7×	76 0.7×	85 1.2×	31 0.5×	28 0.9×	7	177
Jazmín Díaz-Regañón Spain	9	114 0.8×	72 0.7×	78 1.1×	63 1.1×	23 0.7×	15	214
R. Andini Italy	4	187 1.3×	84 0.8×	56 0.8×	67 1.2×	41 1.3×	5	238
Evangelos Vryonis Greece	7	190 1.3×	100 0.9×	80 1.1×	67 1.2×	51 1.6×	11	300

Countries citing papers authored by Fidi Koppel

Since Specialization

Citations

This map shows the geographic impact of Fidi Koppel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fidi Koppel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fidi Koppel more than expected).

Fields of papers citing papers by Fidi Koppel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fidi Koppel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fidi Koppel. The network helps show where Fidi Koppel may publish in the future.

Co-authorship network of co-authors of Fidi Koppel

This figure shows the co-authorship network connecting the top 25 collaborators of Fidi Koppel. A scholar is included among the top collaborators of Fidi Koppel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fidi Koppel. Fidi Koppel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Turjeman‬‏, ‪Adi, Elodie von Dach, José Molina, et al.. (2022). Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine. 55. 101750–101750. 27 indexed citations

2.

Turjeman‬‏, ‪Adi, Elodie von Dach, José Molina, et al.. (2022). Duration of Antibiotic Treatment for Gram-Negative Bacteremia – Systematic Review and Individual Participant Data (IPD) Meta-Analysis. SSRN Electronic Journal. 1 indexed citations

3.

Howard‐Anderson, Jessica, Dafna Yahav, Toshimitsu Hamasaki, et al.. (2022). A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection. Open Forum Infectious Diseases. 9(6). ofac140–ofac140. 9 indexed citations

4.

Bitterman, Roni, Fidi Koppel, Cristina Mussini, et al.. (2021). Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open. 11(2). e040210–e040210. 17 indexed citations

5.

Zusman, Oren, Sergey Altunin, Fidi Koppel, et al.. (2016). Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy. 72(1). 29–39. 129 indexed citations

6.

Koppel, Fidi, et al.. (1992). Indicator bacteria for fecal pollution in the littoral zone of Lake Kinneret. Water Research. 26(11). 1457–1469. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact